# US 8,771,756 B2 · Biocompatible materials for medical devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,756 B2
- Document ID: US8771756B2
- Status: Granted
- Kind: B2
- Application number: 12/979,927
- Filed: 2010-12-28
- Published: 2011-06-30
- Granted: 2014-07-08
- Earliest claimed: 2009-12-28
- Assignees: Colorado State University Research Foundation
- Applicants: Melissa M. Reynolds; Benjamin P. Reynolds
- Inventors: Melissa M. Reynolds; Benjamin P. Reynolds
- Web page: https://patentgrep.com/patent/US8771756B2

## CPC

- C01B 21/265: {characterised by the catalyst}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 29/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 29/146: {Porous materials, e.g. foams or sponges}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/146: {Porous materials, e.g. foams or sponges}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C01B 21/24: Nitric oxide (NO) {(C01B21/203 takes precedence)}
- A61L 2300/114: Nitric oxide, i.e. NO
- A61L 2300/608: having two or more layers
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices comprising a metal-organic framework.

## Claims

### Claim 1

A method of producing nitric oxide comprising: providing a composition comprising a three-dimensional metal-organic framework; exposing the composition to physiological fluid including a nitric-oxide-releasing compound; and continuously producing nitric oxide from the nitric oxide releasing compound via a catalytic reaction catalyzed by the three-dimensional metal-organic framework, wherein the metal-organic framework comprises Cu3(1,3,5-benzenetricarboxylic acid)2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the metal-organic framework has a porous structure.

### Claim 3 (depends on 1)

The method of claim 1, wherein the metal-organic framework has a porous structure comprising pores having an average size of about 5 Å to about 500 Å in diameter.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nitric oxide-releasing compound comprises a functional group selected from the group consisting of S-nitrosothiol, diazeniumdiolate, nitrate, nitrite, nitroso, and nitrosyl.

### Claim 5 (depends on 1)

The method of claim 1, wherein the exposing step comprises contacting the composition with fluids, tissues, or cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the exposing step comprises contacting the composition with blood.

### Claim 7 (depends on 1)

The method of claim 1, wherein the nitric oxide-releasing compound is present in fluids, tissues, or cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the nitric oxide-releasing compound is present in blood.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition comprises a therapeutic agent.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition comprises a therapeutic agent selected from the group consisting of anti-thrombotic agents and antimicrobial agents.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition comprises a polymer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition comprises a polymer selected from the group consisting of polyurethane (PU), polyesters, polyethers, silicones, silicates, poly(vinyl chloride) (PVC), acrylates, methacylates, dextran, synthetic rubber (cis-polyisoprene), polyvinyl acetate, Bakelite, polychloroprene (neoprene), nylon, polystyrene, polyethylene, polypropylene, polyacrylonitrile, polyvinyl butyral (PVB), poly(vinylidene chloride), fluorinated polymers, polytetrafluoroethylene (PTFE), and mixtures and copolymers thereof.

### Claim 13 (depends on 1)

The method of claim 1 further comprising administering the composition in a sufficient amount to a patient to treat a disease, disorder or condition.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering the composition in a sufficient amount to a patient in need thereof to treat a disease, disorder, or condition selected from the group consisting of tumors, local infection, systemic infection, macrophage formation, heart disease, artery and vein damage or disease, tissue injury, vascular legions, initimal hyperplasia, heart failure, high or elevated blood pressure, vasoconstriction, platelet adhesion, platelet aggregation, atherosclerosis, thrombo-embolism, thrombosis, smooth muscle cell proliferation, sepsis, complications with medical devices, wounds caused by incisions or insertion of medical devices, cicatrices, endothelial cell damage, arrhythmias, heart defects, congenital heart defects, cell overgrowth, and soft bones.

### Claim 15 (depends on 1)

The method of claim 1, wherein the composition produces nitric oxide at catalytic sites on the metal-organic framework for at least 7 days.

### Claim 16 (depends on 1)

The method of claim 1, further comprising administering the composition in a sufficient amount to a patient to treat biofouling.